Recent Updates
Recently added Catalysts

GSK Biologicals' HIV vaccine

Phase 2

AIDS | Monoclonal antibody | Other |GSK plc|Last Updated: Aug 17, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment28
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00972725Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine DosePHASE2 COMPLETED 28Dec 1, 2009Oct 4, 2010Aug 17, 20181 Belgium
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Subjects With Frequency of Cluster of Differentiation 8 (CD8+) T Cells Expressing at Least One Cytokine to at Least 1, 2, 3 or All 4 Antigens
At Day 14

Among expressed cytokines were interleukin-2 (IL-2), tumour necrosis factor alpha (TNF-α) and interferon gamma (INF-γ), as determined by intracellular cytokine staining (ICS).

Number of Subjects With Solicited Local Symptoms
During the 7 Day (Days 0-6) post-vaccination period

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.

Number of Subjects With Solicited General Symptoms
During the 7 Day (Days 0-6) post-vaccination period

Assessed solicited general symptoms were fatigue, temperature \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], gastrointestinal symptoms \[nausea, vomiting, diarrhoea and/or abdominal pain\] and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Number of Subjects With Unsolicited Adverse Events (AEs)
During the 32 Day (Days 2-29) post-chloroquine administration and during the 30 Day (Days 0-29) post-vaccine administration period

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Number of Subjects With Serious Adverse Events (SAEs)
During the entire study period (from Day 0 up to Day 360)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Number of Subjects With AEs of Specific Interest and Immune-Mediated Disorders (IMDs)
During the entire study period (from Day 0 up to Day 360)

Adverse events of specific interest include auto-immune diseases (AID) and immune mediated disorders such as neurological/demyelinating events, rheumatic and connective diseases, autoimmune endocrine diseases, inflammatory bowel diseases, autoimmune blood disorders, inflammatory skin disorders, other autoimmune/inflammatory events.

Levels of Haematological and Biochemical Parameters
At Day 0

Among haematological and biochemical parameters determined were alanine aminotransferase \[ALT\], aspartate aminotransferase \[ASA\], basophils \[BASO\], creatinine \[CREA\], eosinophils \[EOS\], haematocrit \[HAEM\], haemoglobin \[HAEMO\], lymphocytes \[LYMPH\], monocytes \[MONO\], neutrophils \[NEU\], platelets \[PLA\], red blood cells \[RBC\], urea \[UR\] and white blood cells \[WBC\]. Levels of haematological/biochemical parameters assessed in relation to normal laboratory values were - unknown, below, within and above.

Secondary Endpoints
Magnitude of Antigen Specific CD8+ T Cells Expressing at Least One Cytokine
At Day 0, 7, 14, 30 and 180
Frequency of Antigen (RT) Specific CD8+ T Cells Expressing at Least One Marker/ Cytokine
At Day 0, 7, 14, 30 and 180
Frequency of Antigen (Nef) Specific CD8+ T Cells Expressing at Least One Marker/ Cytokine
At Day 0, 7, 14, 30 and 180
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
GSK732461+Nivaquine GroupEXPERIMENTALSubjects received a single dose of Nivaquine® tablets orally, 2 days prior to receiving a booster dose of the GSK732461 vaccine.
GSK732461 GroupACTIVE_COMPARATORSubjects received a booster dose of the GSK732461 vaccine intramuscularly, in the deltoid region of the non-dominant arm.
Interventions
NameTypeDescription
GSK Biologicals' HIV vaccine (732461)BIOLOGICAL1 dose intramuscular injection
ChloroquineDRUGOne dose of 300 mg
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 52 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * A male or female between, and including, 18 to 52 years of age at the time of vaccination. * Written informed consent prior to any study related procedure on the subject. * Subjects who the investigator believes that they can and will comply with the requirements of the protoc...

Countries:Belgium
Unlock Eligibility Criteria